Your SlideShare is downloading. ×
0
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
The science of drug abuse and addiction prevention
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

The science of drug abuse and addiction prevention

760

Published on

Published in: Health & Medicine
0 Comments
3 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
760
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
145
Comments
0
Likes
3
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • NIDA's mission is to lead the nation in bringing the power of science to bear on drug abuse and addiction. Recent scientific advances have revolutionized our understanding of drug abuse and addiction, which is now recognized as a chronic relapsing brain disease expressed in the form of compulsive behaviors. This understanding has improved our ability to both prevent and treat addiction.
  • The effects of drug abuse are wide ranging and affect people of all ages. Besides addiction, drug abuse is linked to a variety of health problems, including HIV/AIDS, cancer, heart disease, and many more. It is also linked to homelessness, crime, and violence. Thus, addiction is costly to both individuals and society.
  • Among the most serious health consequences of addiction is the transmission of HIV. In addition to the well known risks associated with injection drug use (i.e., transmission through needle and other equipment sharing), are the risks stemming from drug or alcohol intoxication, which can alter a person’s judgment, and increase the probability of high-risk behaviors, such as unprotected sex.
  • Drug abuse costs the United States economy hundreds of billions of dollars in increased health care costs, crime, and lost productivity. The total costs of drug abuse and addiction due to use of tobacco, alcohol and illegal drugs are estimated at $524 billion a year. Illicit drug use alone accounts for $181 billion in health care, productivity loss, crime, incarceration and drug enforcement.
  • Decades of research have revealed addiction to be a disease that alters the brain. We now know that while the initial decision to use drugs is voluntary, drug addiction is a disease of the brain that compels a person to become singularly obsessed with obtaining and abusing drugs despite their many adverse health and life consequences.
  • Science has come a long way in helping us understand how drugs of abuse change the brain. Research has revealed that addiction affects the brain circuits involved in reward, motivation, memory, and inhibitory control. When these circuits are disrupted, so is a person’s capacity to freely choose not to use drugs, even when it means losing everything they used to value. In fact, the inability to stop is the essence of addiction, like riding in a car with no brakes.
  • Drugs of abuse change the brain, and new technologies are showing us how. Indeed we’ve come a long way from this primitive depiction of a “brain on drugs.”
  • We can now measure the brain’s response to drugs of abuse in real time. This slide depicts images of a human brain taken at different intervals following administration of radioactive cocaine. Because the drug was “radiolabeled,” scientists can see precisely where cocaine binds in the brain (yellow signal) and for how long. Studies such as these teach scientists more about how cocaine exerts its devastating effects, and can illustrate to people in real time what happens to their brains on drugs.
     
  • Addiction is similar to other chronic diseases. Using imaging technology to measure metabolism (in this case, glucose uptake) in the brain and heart, one can see that both addiction and heart disease produce observable changes in organ function. In each pair of images shown above, the healthy organ shows greater activity (reds and yellows) than the diseased organ. In drug addiction, the frontal cortex, which is a part of the brain associated with judgment and decision-making, is significantly affected. Like heart disease, drug addiction can be prevented and treated successfully. If left untreated, however, its effects can last a lifetime.
  • Research has also taught us that addiction is a complex disease, influenced by a multitude of highly entangled factors. No single factor determines whether someone will or will not become addicted to drugs.
  • Addiction usually begins in adolescence, thus early prevention is critical. This slide illustrates the age at which drug dependence is first diagnosed, which for tobacco, alcohol and marijuana, is typically in adolescence or early adulthood. Much of the research supported by NIDA is aimed at preventing drug use from ever starting. This research ranges from highly complex molecular and imaging studies to devising effective messages that “speak” to young people.
  • Why would anyone abuse drugs? Research has shown that people generally take drugs to either feel good (i.e., sensation seekers or anyone wanting to experiment with feeling high or different) or to feel better (i.e., self-medicators or individuals who take drugs in an attempt to cope with difficult problems or situations, including stress, trauma, and symptoms of mental disorders).
    Images: courtesy of Vivian Felsen
  • Why do drugs make people feel good or feel better—because of what they do to their brain. Drugs exert their effects largely on the motivation and pleasure pathways of the brain.
  • How are drugs able to affect brain chemicals? Often, the chemical structure of drugs is similar to brain chemicals or neurotransmitters. Similarity in structure allows them to be recognized by neurons and to alter normal brain messages. Illustrated in this slide is THC, the active ingredient found in marijuana. It’s chemical structure is highly similar to anandamide, which is involved in a variety of functions including regulation of pain, appetite, memory, and mood.
  • Dopamine is a brain chemical involved in many different functions including movement, motivation, reward — and addiction. Nearly all drugs of abuse directly or indirectly increase dopamine in the pleasure and motivation pathways and in so doing, alter the normal communication between neurons.
  • Neurons are the brain’s messaging system. How do they communicate with each other? The brain consists of billions of neurons, or nerve cells, that communicate via chemical messages. This is a schematic drawing of a neuron. Towards the left of the diagram is the cell body, where neurotransmitters are made. Extending outward from the cell body are dendrites, which receive information from other neurons. When the cell body is sufficiently stimulated, an electric pulse called an action potential is generated and subsequently travels down the axon to the terminal region of the cell. Fast transmission of this electrical message is aided by an insulator material covering the axon called myelin. Once the impulse reaches the nerve terminal, neurotransmitters, such as dopamine are released into the synapse or gap between neurons. These chemicals can then attach to receptors located on the dendrites of neighboring neurons, thus transmitting information from one cell to the next within the brain and other parts of the body. Some axons can travel a long distance, extending all the way from your brain to your toes!
  • This slide and the one that follows show how neurotransmission works specifically for dopamine. What is schematically illustrated in this slide is a nerve terminal (top), the synaptic cleft or space between the neurons, and the post-synaptic or receiving portion of a dendrite on a neighboring neuron. Dopamine is contained in vesicles (round storage sites) in the nerve terminal; dopamine receptors are present on the receiving (bottom) neuron.
  • When a signal comes down the axon, dopamine (shown in orange) is released into the synapse. It then crosses the synaptic cleft to the second neuron, where it binds to and stimulates dopamine receptors (shown in blue), generating a signal in the second neuron. The dopamine is then released from the receptor and crosses back to the first neuron where it is picked up by dopamine transporters (reuptake molecules; shown in purple) for re-use.
  • Natural rewards stimulate dopamine neurotransmission. Eating something that you enjoy or being stimulated sexually can cause dopamine levels to increase. In these graphs, dopamine is being measured inside the brains of animals. Its increase is shown in response to food or sex cues. This basic mechanism of controlled dopamine release and reuptake has been carefully shaped and calibrated by evolution to reward normal activities critical for our survival.
  • But what happens when a person takes a drug? This slide shows how cocaine is able to alter activity in the synapse. Cocaine (shown in green), attaches to dopamine transporters (shown in purple), thereby blocking dopamine from being taken back up by the first neuron. Thus dopamine can continue to stimulate (maybe over-stimulate) the receptors of the second neuron because it remains in the synapse for a longer period of time. This duration of stimulation and amount of dopamine in the synapse is far greater than what normally occurs when a person engages in an enjoyable activity (e.g., eating, sex, etc), and is what produces cocaine’s intense euphoria and potential for abuse.
  • Nearly all drugs of abuse increase dopamine neurotransmission. This slide shows the increase in brain dopamine (DA) levels (measured in animals) following exposure to various drugs of abuse. All of the drugs depicted in this slide have different mechanisms of action, however they all increase activity in the brain reward pathway by increasing dopamine neurotransmission. It is because drugs activate these brain regionsusually more effectively and for longer periods of time than natural rewardsthat they have an inherent risk of being abused.
  • Dopamine is an important brain chemical in drug abuse and addiction, but other brain systems and brain chemicals are also involved. Serotonin and glutamate neurotransmitter systems, for example, are among those affected. These neurotransmitters are important regulators of mood, sleep, learning and memory, and more.
  • Brain pathways affected by drugs of abuse. The dopamine and serotonin pathways are two brain systems affected by drugs of abuse. They are illustrated here.  By altering activity in these pathways, abused substances can influence their function. Dopamine neurons (shown in yellow) influence pleasure, motivation, motor function and saliency of stimuli or events. Serotonin (shown in red) plays a role in learning, memory, sleep and mood.
  • Prolonged drug abuse changes the brain in fundamental ways that reinforce drug taking and lead to addiction. These changes are difficult to un-do and may last a long time.
  • Drug abuse changes both the structure of the brain and its functioning. Research in humans and in animal models demonstrates that repeated exposure to drugs of abuse alters brain function and behavior. Therefore, early intervention is key—before brain changes take hold and drug abuse becomes compulsive.
  • Exposure to some drugs of abuse can change the structure of neurons in the brain. Stimulants like amphetamines can alter the structure of neurons. In this case, the dendrites of dopamine neurons in the nucleus accumbens—a part of the reward pathway—have more dendritic spines or connections in the amphetamine exposed animal compared to one treated only with saline.
  • Repeated drug exposure also changes brain function. Positron emission tomography (PET) images show similar changes in brain dopamine receptors resulting from addiction to different substances. Dopamine D2 receptors are one of five types of receptors that bind dopamine in the brain. The brain images on the left are those of controls, while those on the right are from individuals addicted to cocaine, methamphetamine, alcohol, or heroin. The striatum (which contains the reward and motor circuitry) shows up as bright red and yellow in the controls (in the left column), indicating numerous D2 receptors. Conversely, the brains of addicted individuals (in the right column) show a less intense signal, indicating lower levels of D2 receptors. This reduction likely stems from repeated over-stimulation of the dopamine receptors. Brain adaptations such as this contribute to the compulsion to abuse drugs.
  • Another example: Methamphetamine abuse decreases dopamine transporter activity and compromises mental function. The brain image at the top left is a PET image from a normal control subject. The striatum is brightly lit in red and yellow, indicating the presence of many dopamine transporters, which contrasts with the brain of a methamphetamine abuser (bottom left). What does this mean functionally? The graphs on the right show the relationship between performance on a motor (upper right) and a memory task (lower right) and methamphetamine-driven decreases in dopamine transporters. The magnitude of the decline in the dopamine transporter binding is positively correlated with the extent of motor and memory impairment; thus the greater the decline, the greater the impairment in memory and motor reaction time.
  • Research has identified a number of brain circuits that are affected by drug abuse and addiction. The areas depicted contain the circuits that underlie feelings of reward, learning and memory, motivation and drive, and inhibitory control. Each of these brain areas and the behaviors they control must be considered when developing strategies to treat drug addiction.
    Key:
    PFC – prefrontal cortex; ACG – anterior cingulate gyrus; OFC – orbitofrontal cortex; SCC – subcallosal cortex; NAc – nucleus accumbens; VP – ventral pallidum; Hipp – hippocampus; Amyg – amygdala
  • To address the devastating consequences of drug abuse and addiction, NIDA-sponsored research is largely focused on three main areas: Drug Prevention, Addiction Treatment and HIV/AIDS. Prevention research examines a wide range of topics, including the contributions of genetics, environment, and development, as well as the impact of comorbid conditions on susceptibility to drug abuse.
  • Addiction is a developmental disease that usually begins in adolescence. For example, 67 percent of those who try marijuana for the first time are between the ages of 12 and 17. Prevention efforts are therefore of primary importance—to stop drug abuse before it ever starts.
  • Research shows that brain development continues throughout adolescence and into early adulthood.
  • Magnetic Resonance Imaging (MRI) Scans allow us to map the maturation of the brain. This slide illustrates brain development through early adulthood, with blue indicating the mature state. The prefrontal cortex (white circle), which governs judgment and decision-making functions, is the last part of the brain to develop. This may help explain why teens, who are more prone to participating in risk-taking behavior, are particularly vulnerable to drug abuse.
  • Adolescents’ brains are “wired” differently than adults. Because the prefrontal cortex is one of the last areas of the brain to mature, adolescents tend to use other areas of the brain – in this case emotional areas – when making decisions. For example, brain activity, seen here via functional MRI, shows that when judging emotion represented on a face, a teenager’s amygdala (right) is activated. Activity in the amygdala during this task likely reflects more of a gut reaction than a reasoned one. In contrast, the prefrontal cortex, involved in reasoning and reflection is activated in the adult brain (shown on the left).
  • Given the different physiology of adolescents’ brains, do they react differently to substances of abuse? Research findings point to “yes.”
  • Animal studies show a difference in response to drugs of abuse in early-exposed “adolescents.” Rats first exposed to nicotine as adolescents self-administer nicotine more often and in higher total doses per session than rats first exposed as adults. Corresponding and persistent changes in the brain were also found in those animals that were exposed early to nicotine.
  • NIDA is supporting research to learn more about how to best prevent drug abuse and treat drug addiction in adolescents. One important area is understanding adolescent decision-making, including the social and biological factors that influence the decision to use drugs.
  • What factors affect vulnerability to drug abuse and addiction? Vulnerability is a product of the interaction of a person’s biology (including their genes), environment, and age. These interactions are complex and difficult to tease apart.
  • For example, the level of dopamine receptors in a person’s brain can influence whether they “like or dislike” the effects of a particular drug. Because dopamine is involved in the rewarding effects of drugs of abuse, it was hypothesized in this study that normal variation in the of number of dopamine receptors in a person’s brain could influence their response to drug exposure. To test this, human subjects were given the stimulant methylphenidate (Ritalin), their brains’ were imaged using PET, and they were asked whether they liked or disliked the drug’s effects. Those subjects who had high levels of dopamine receptors found the experience unpleasant, while those with lower levels of dopamine found it more pleasurable. This suggests that individual differences in a marker of dopamine function can influence an person’s susceptibility to continued drug abuse.
  • Studies have shown that 40-60 percent of the predisposition to addiction can be attributed to genetics. This is not just the risk conveyed by genes themselves, but also the added impact of the environment on how those genes function or are expressed. Taking drugs is, of course, a necessary environmental risk factor for addiction, but so are exposures to stress and peers who use drugs. Growing knowledge about the dynamic interactions of genes with the environment and developmental stage confirms addiction as a complex and chronic disease of the brain with many contributors to its expression in individuals. 
  • Genome wide analyses are being used to identify novel candidate genes that increase the risk for addiction. This slide illustrates convergent findings from different laboratories identifiying a cluster of three nicotinic receptor subunit genes (3 5 4) linked to smoking quantity, nicotine dependence, and the risk of two smoking-related diseases––lung cancer and peripheral arterial disease. This new information on genetic vulnerability also suggests novel targets for the development of medications to treat tobacco addiction and related diseases.
  • What Other Biological Factors Contribute to Addiction—Comorbidity. The prevalence of addiction to illicit drugs (left) and to nicotine (right) is higher in patients who also suffer from comorbid mental illnesses.
  • The converse is also true: substance abusers experience higher rates of other comorbid mental illnesses than the general population. Although comorbidity is common, causality is more difficult to demonstrate.
  • Why? Possible reasons that mental illnesses and substance abuse tend to co-occur include: (1) the propensity for people to self-medicate in order to relieve mental distress or illness; (2) the increased risk for mental illness brought on by drug abuse, especially in those with genetic or other vulnerabilities; and (3) the overlap of risk factors for both conditions. Understanding the various contributions of these factors will help us develop more effective prevention and treatment interventions for both drug abuse and other mental disorders.
  • Many environmental factors also contribute to a person’s propensity to take drugs of abuse. These include having a history of physical or sexual abuse, witnessing violence, or experiencing other kinds of stressors. Drug availability is, of course, a primary environmental factor in contributing to drug abuse and addiction.
  • How can the environment shape the response to drugs? This study in non-human primates shows how social factors can influence the level of dopamine receptors and the propensity to self administer drugs. Illustrated above are PET images of the brains of monkeys that were initially individually housed (left) and then group housed (right). Those emerging at the top of their social rank – experiencing less stress and more access to natural rewards – expressed more dopamine receptors (bright yellow) and took less cocaine than did submissive monkeys (green symbols on graph).
  • Knowledge from scientific research has prompted notable shifts in attitudes and behaviors toward drug abuse. We now know that drug abuse can be prevented and approaches to prevention have been identified and put into practice. NIDA’s booklet, Preventing Drug Use among Children and Adolescents, provides research-based principles for preventing drug abuse.
  • Prevention messages can make a difference.  They can convey information to change attitudes about drug use, which can in turn change behavior.  For example, as perceived risk associated with marijuana use increases, its abuse decreases.
  • To address the devastating consequences of drug abuse and addiction, NIDA’s large research portfolio is focused on three main areas: drug abuse prevention, addiction treatment, and HIV/AIDS. Treatment research examines 1) why people need help to achieve abstinence; 2) behavioral and pharmacological approaches to treat addiction; and 3) how best to provide a continuum of care approach to addiction treatment based on what we now understand about addiction as a chronic, but treatable disease.
  • Addiction changes brain circuitry, making it hard to “apply the brakes” to detrimental behaviors. In the non-addicted brain, control mechanisms constantly assess the value of stimuli and the appropriateness of the planned response. Inhibitory control is then applied as needed. In the addicted brain, this control circuit becomes impaired because of drug use and loses much of its inhibitory power over the circuits that drive responses to stimuli deemed salient.
  • Treatment is therefore essential. Most people addicted to substances cannot quit on their own.
  • Addiction requires treatment that addresses its complexity. Substance abuse treatment should address the whole person and can include medications, behavioral therapies, and ancillary support services.
  • Treatment Can Work! More than 30 years of research have shown this to be true. Behavioral therapies can engage people in treatment, modify their attitudes and behaviors related to drug abuse, and increase their life skills. Medications are now available to treat opioid, alcohol, and tobacco addiction, while others are on the horizon. Behavioral therapies can enhance the effectiveness of these medications and can help people stay in treatment longer.
  • NIDA is bringing the power of science to bear on drug abuse and addiction. Research continues to uncover linkages to mechanisms that will inform the development of effective treatment approaches.
  • Basic research has led to the identification of several potential medications for drug addiction. In addition to already approved medications for treatment of opiate addiction (e.g., methadone, buprenorphine), new approaches that target different aspects of addiction are also being developed. For example, the cannabinoid receptor system (CB1) is currently being targeted for medications to treat nicotine, alcohol and other drug addictions, as well as obesity. Drug metabolism can also be a factor in addiction susceptibility by altering the pharmacokinetics and reinforcing effects of drugs. Smokers who are poor metabolizers of nicotine smoke less and may be less vulnerable to addiction. Medications can be developed to take advantage of that quality. Finally, animal models of relapse have allowed testing of medications that inhibit triggers of drug seeking behavior, including stress. Corticotropin releasing factor (CRF) antagonists are being explored as possible medications as they inhibit the stress response and the resultant drug seeking behavior.
  • But medications alone are not enough. Drug addiction, like other chronic diseases requires long-term treatment to help people get to a point where they can manage their recovery and regain their lives.
  • Relapse rates for drug addiction are similar to those of other well-characterized chronic illnesses. This slide compares relapse rates for drug-addicted patients with those suffering from diabetes, hypertension, and asthma. Relapse is common and similar across these illnesses (as is adherence to medication). Thus, drug addiction should be treated like any other chronic illness, with relapse serving as a trigger for renewed intervention.
  • Drug addiction resembles other chronic diseases in more ways than relapse rates. These include both biological and behavioral components that need to be addressed during treatment, an expectation of long-term recovery requiring repeated episodes of treatment and the added value of support programs in sustaining it.
  • People do recover from drug abuse and addiction. Research bears this out.
  • Extended abstinence is predictive of sustained recovery. The odds of remaining abstinent rise if patients have been abstinent for 1 to 3 years. After 3 years, the recovery odds remain high and stable. Therefore, as with other chronic diseases, addiction requires an ongoing and active disease management strategy.
  • It takes time, but the brain can recover. This slide shows images of dopamine transporter (DAT) binding in three brains: (1) a healthy control (top); (2) a methamphetamine abuser one month after discontinuing drug abuse (middle); and (3) a methamphetamine abuser after 14 months of abstinence (bottom). The control brain shows a robust concentration of dopamine transporters in the striatum (red and yellow), while the methamphetamine abuser has a dramatic drop in DAT binding, even a month after drug abuse has stopped. Sustained abstinence, however, allows a near-full return of DAT binding to normal levels. Still, some of the behavioral effects of methamphetamine do not completely return to normal (not shown). This means that it can take a long time to recover from methamphetamine abuse, but recovery is possible.
  • Drug abuse treatment works and brings about reductions not just in drug abuse, but also in criminal recidivism. A therapeutic community approach (CREST) was tested in prison and continued during participants’ transition back to the community. Among those who completed treatment and aftercare programs, 35% remained drug free, and 69% were not arrested within three years of release from incarceration. These reductions in turn yield significant cost savings and provide hope for families and communities devastated by addiction.
  • Addiction treatment aims to help people achieve abstinence and become full participants in society. Ancillary support services, in addition to behavioral and pharmacological treatments, help to connect people to needed social, medical, and employment services, to get their lives back on track.
  • To address the devastating consequences of drug abuse and addiction, much of the research supported by NIDA is focused on three main areas: drug prevention, addiction treatment and HIV/AIDS.
    HIV/AIDS research focuses on 1) understanding the intertwined epidemics of drugs abuse and HIV/AIDS; 2) drug treatment as HIV prevention; 3) enhancing screening and referral to treatment among high risk populations; 4) reducing the disparate health outcomes for minorities who are disproportionately affected by the HIV epidemic; and 5) contributing to international efforts to reduce the spread of HIV.
  • Drug abuse and HIV/AIDS are intertwined epidemics in ways that go beyond the sharing of drug injection equipment. While injection drug users are still at great risk, anyone under the influence of drugs or alcohol is also at heightened risk of contracting or transmitting HIV. Drug abuse can also contribute to a more serious HIV disease progression, possibly through direct effects or interactions with HIV on the immune system, and also by adversely impacting adherence to HIV treatment. Finally, because highly active antiretroviral therapy (HAART) is enabling more people to live longer with HIV, HIV is being redefined as a chronic illness with associated medical disease consequences, particularly for the brain.
  • Injection drug use has contributed to nearly one third of the cases of HIV in this country since the epidemic began. But the epidemic is changing––effective medications and HIV risk-reduction interventions in intravenous drug abusers have helped to curb the spread of HIV occurring though injection drug use (blue line), while transmission through heterosexual contact is increasing.
  • Rates of HIV infection are converging in drug abusers who inject drugs and those who do not inject. HIV is being spread among drug abusers by means other than needle sharing. Drug addiction leads people to engage in risky behaviors (e.g. using sex to procure drugs or money) and drug use impairs people’s judgment and lowers their inhibitions, which can lead to impulsive and unsafe behaviors. Therefore, effective drug abuse treatment is also HIV prevention. Indeed, the integration of HIV risk-reduction interventions into drug abuse treatment is imperative.
  • While all racial/ethnic groups are affected by HIV/AIDS, not all are affected equally. Associated health disparities fall disproportionately on ethnic minorities, particularly African Americans, who are at especially high risk for developing AIDS. Even though they comprise only 13 percent of the U.S. population, African Americans accounted for approximately half of the total AIDS cases diagnosed in 2005. In fact, while the proportion of AIDS diagnoses among whites (not Hispanic) has decreased; the proportions among non-Hispanic African Americans and Hispanics have increased.
  • Evidence shows that drug abuse can worsen HIV consequences in the brain. PET brain scans shown here demonstrate that cocaine abuse accelerates the deficits observed in the dopamine system in patients with HIV.
  • NIDA’s work with HIV/AIDS and drug abuse prevention has an international reach. International collaboration facilitates widespread information exchange and dissemination.
  • Drug abuse is a global problem. An international focus allows the sharing of important findings with a wider audience, particularly benefiting those countries where HIV/AIDS is highly prevalent. It also allows researchers to take advantage of the unique cultural, biological, and environmental factors that exist in different regions of the world, which can reveal important and novel information about our shared health concerns regarding drug abuse and HIV.
  • NIDA’s international program makes significant contributions to drug abuse research. These include funding and training, priority setting, conference sponsorship, and information dissemination.
  • Our top priorities remain: to advance the science through research and erase the stigma through education. Through sponsoring pivotal research and working with others, NIDA is bringing new insights into the mechanisms of addiction to communities around the country, helping to reduce associated stigma and suffering.
  • Transcript

    • 1. Bringing the Full Power of Science to Bear on Drug Abuse & Addiction
    • 2. Neurotoxicity AIDS, Cancer Mental illness Homelessness Crime Violence Health care Productivity Accidents
    • 3. 4 Out of 10 U.S. AIDS Deaths Are Related to Drug Abuse
    • 4. Estimated Economic Cost to Society Due to Substance Abuse and Addiction: Illegal drugs: Alcohol: Tobacco: $181 billion/year $185 billion/year $158 billion/year Total: $524 billion/year Surgeon General’s Report, 2004; ONDCP, 2004; Harwood, 2000.
    • 5. What is Addiction? Addiction is A Brain Disease • Characterized by: – Compulsive Behavior – Continued abuse of drugs despite negative consequences – Persistent changes in the brain’s structure and function
    • 6. Advances in science have revolutionized our fundamental views of drug abuse and addiction.
    • 7. Your Brain on Drugs in the 1980’s
    • 8. Your Brain on Drugs Today YELLOW shows places in brain where cocaine binds (e.g., striatum) Fowler et al., Synapse, 1989.
    • 9. Addiction is Like Other Diseases…     It is preventable It is treatable It changes biology If untreated, it can last a lifetime Decreased Brain Metabolism in Drug Abuser Decreased Heart Metabolism in Heart Disease Patient High Healthy Brain Diseased Brain/ Cocaine Abuser Low Healthy Heart Research supported by NIDA addresses all of these components of addiction. Diseased Heart
    • 10. Addiction Involves Multiple Factors
    • 11. % in each age group who develop first-time dependence Addiction Is A Developmental Disease that starts in adolescence and childhood 1.8% 1.8% TOBACCO 1.6% 1.6% 1.4% 1.4% CANNABIS ALCOHOL 1.2% 1.2% 1.0% 1.0% 0.8% 0.8% 0.6% 0.6% 0.4% 0.4% 0.2% 0.2% 0.0% 0.0% 5 5 10 15 10 15 21 25 30 35 40 45 50 55 60 65 21 25 30 35 40 45 50 55 60 65 Age Age at tobacco, alcohol, and cannabis dependence per DSM IV National Epidemiologic Survey on Alcohol and Related Conditions, 2003.
    • 12. Why Do People Take Drugs in The First Place? To Feel Good To Feel Better To have novel: feelings sensations experiences AND to share them To lessen: anxiety worries fears depression hopelessness
    • 13. Why Do People Abuse Drugs? Drugs of Abuse Engage Motivation and Pleasure Pathways of the Brain
    • 14. Drugs can be “Imposters” of Brain Messages
    • 15. Movement Motivation Dopamine Addiction Reward & well-being
    • 16. The Neuron: How the Brain’s Messaging System Works Dendrites Axon Cell body (the cell’s life support center) Terminal branches of axon Neuronal Impulse Myelin sheath Donald Bliss, MAPB, Medical Illustration
    • 17. dopamine transporters
    • 18. Natural Rewards Elevate Dopamine Levels % of Basal DA Output 200 DA Concentration (% Baseline) Food NAc shell 150 100 50 Empty Box Feeding 0 0 60 120 Time (min) 180 Sex 200 150 100 Sample 1 Number Female Present 2 Di Chiara et al., Neuroscience, 1999.,Fiorino and Phillips, J. Neuroscience, 1997. 3 4 5 6 7 8
    • 19. Effects of Drugs on Dopamine Release Accumbens DA DOPAC HVA 0 1 2 3 4 100 0 1 2 Time After Drug Di Chiara and Imperato, PNAS, 1988 0 1 250 Accumbens 150 0 DA DOPAC HVA 100 5 hr Accumbens Caudate 3 hr Cocaine 200 Nicotine 200 Accumbens 300 0 250 % of Basal Release 400 % of Basal Release 1100 1000 900 800 700 600 500 400 300 200 100 0 % of Basal Release % of Basal Release Amphetamine 2 3 4 5 hr Morphine Dose 0.5 mg/kg 1.0 mg/kg 2.5mg/kg 10 mg/kg 200 150 100 0 0 1 2 3 Time After Drug 4 5 hr
    • 20. But Dopamine is only Part of the Story • Scientific research has shown that other neurotransmitter systems are also affected: – Serotonin – Regulates mood, sleep, etc. – Glutamate – Regulates learning and memory, etc.
    • 21. Science Has Generated Much Evidence Showing That… Prolonged Drug Use Changes the Brain In Fundamental and Long-Lasting Ways
    • 22. AND… We Have Evidence That These Changes Can Be Both Structural and Functional
    • 23. Structurally… Neuronal Dendrites in the Nucleus Accumbens Saline Amph Robinson & Kolb, Journal of Neuroscience, Volume: 1997
    • 24. Functionally… Dopamine D2 Receptors are Decreased by Addiction DA D2 Receptor Availability Cocaine Meth Alcohol Heroin Control Addicted
    • 25. Normal Control Dopamine Transporter Bmax/Kd Dopamine Transporters in Methamphetamine Abusers 2.0 1.8 1.6 1.4 1.2 1.0 7 Motor Task Loss of dopamine transporters in methamphetamine abusers may result in slowing of motor reactions. 8 9 10 11 12 13 Time Gait (seconds) 2.0 1.8 1.6 1.4 1.2 1.0 16 14 12 10 Memory Task Loss of dopamine transporters in methamphetamine abusers may result in memory impairment. 8 6 Delayed Recall (words remembered) Methamphetamine Abuser 4 Volkow et al., Am. J. Psychiatry, 2001.
    • 26. Implication? Brain changes resulting from prolonged use of drugs may compromise mental AND motor function.
    • 27. Circuits Involved In Drug Abuse and Addiction All of these brain regions must be considered in developing strategies to effectively treat addiction
    • 28. Priority Research Areas Prevention genetics environment development co-morbidity (Children & Adolescents) Treatment (New Targets & New Strategies) HIV/AIDS
    • 29. Addiction is a Developmental Disease: It Starts Early 67% First Marijuana Use, (Percent of Initiates) 100 26% 5.5% 10 1.5% 1 Child <12 Teen 12-17 Young Adult 18-25 Adult >25
    • 30. Basic Science Tells Us that Adolescents’ Brains Are Still Developing…
    • 31. MRI Scans of Healthy Children and Teens Over Time Copyright ©2004 by the National Academy of Sciences Gogtay, Giedd, et al. Proc. Natl. Acad. Sci., 2004
    • 32. When Reading Emotion… Adults Rely More on the Frontal Cortex While Teens Rely More on the Amygdala Deborah Yurgelon-Todd 2000.
    • 33. Do Adolescents React Differently than Adults to Substances of Abuse?
    • 34. Rats Exposed to Nicotine in Adolescence Self-Administer More Nicotine Than Rats First Exposed as Adults Collins et al, Neuropharmacology, 2004, Levin et al, Psychopharmacology, 2003
    • 35. Do We Need Fundamentally Different Strategies At Different Stages of Adolescence?
    • 36. Vulnerability Why do some people become addicted to drugs while others do not?
    • 37. Individual Differences in Response to Drugs: DA Receptors influence drug liking High DA receptor high Low DA receptor low As a group, subjects with low receptor levels found MP pleasant while those with high levels found MP unpleasant Adapted from Volkow et al., Am. J. Psychiatry, 1999.
    • 38. Genetics is a Big Contributor to the Risk of Addiction… And… The Nature of this Contribution Is Extremely Complex
    • 39. Gene Cluster is Associated with Nicotine Dependence
    • 40. What Other Biological Factors Contribute to Addiction--Comorbidity Prevalence of Nicotine Addiction Prevalence of Drug Disorders 40 35 80 25 Percent Percent 30 20 15 10 60 40 20 5 lic op hr e l P ed A ia c iz al So er en G y et xi n Sc hi z a pu b i ob h G en er al r er de sion nia bia i c ord r o bl i s iso res Ma ph pu D D ep a r al d y D go ut er oo iet n M A x e / o ia G ny w / c w ho b An A i p ic ny an Pan ora A P g ni a 0 0 ep D re io ss n
    • 41. COMORBIDITY
    • 42. Why do Mental Illnesses and Substance Abuse Co-occur? • Self-medication – substance abuse begins as a means to alleviate symptoms of mental illness • Causal effects – Substance abuse may increase vulnerability to mental illness • Common or correlated causes – the risk factors that give rise to mental illness and substance abuse may be related or overlap
    • 43. What Environmental Factors Contribute to Addiction? • Stress • Early physical or sexual abuse • Witnessing violence • Peers who use drugs • Drug availability
    • 44. Individually Housed Group Housed Becomes Dominant No longer stressed Becomes Subordinate Stress remains Reinforcers (per session) Social Stressor Affects Brain DA D2 Receptors and Drug Self-Administration Subordinate Dominant 50 40 30 * * 20 10 0 S.003 .01 .03 .1 Cocaine (mg/kg/injection) Morgan, D. et al., Nature Neuroscience, 2002.
    • 45. Prevention Works: Knowledge of Risk and Protective Factors Has Led to the Development of Effective Prevention Strategies
    • 46. Changes in Attitudes Lead to Changes in Use 60 50 40 30 20 10 0 75 77 79 81 83 85 87 89 91 93 95 97 99 01 03 05 07 Past Year Use Monitoring the Future Study, 2007. Perceived Risk
    • 47. Priority Areas Prevention Research (Children & Adolescents) genetics environment development co-morbidity Treatment Research (New Targets & New Strategies) HIV/AIDS Research
    • 48. Why Can’t Addicts Just Quit? Non-Addicted Brain Addicted Brain Control Control Saliency Drive NO GO Memory Saliency Drive GO Memory Because Addiction Changes Brain Circuits Adapted from Volkow et al., Neuropharmacology,
    • 49. This is why addicts can’t just quit. and… This is why treatment is essential.
    • 50. Treating a Biobehavioral Disorder Must Go Beyond Just Fixing the Chemistry We Need to Treat the Whole Person! Pharmacological Treatments (Medications) Medical Services Behavioral Therapies Social Services In Social Context
    • 51. Treatment Can Work! Principles of Treatment • No single treatment is appropriate for all individuals. • Treatment needs to be readily available. • Treatment must attend to multiple needs of the individual, not just drug use. • Multiple courses of treatment may be required for success. • Remaining in treatment for an adequate period of time is critical for treatment effectiveness.
    • 52. We Are Using Science to Develop Even Better Treatments Genetics Mechanisms Treatments
    • 53. Basic Research Medication Opiate agonists stabilize brain function in heroin addicts Agonist Therapy Methadone Buprenorphine CB1 KO mice have decreased responses to multiple drugs of abuse CB1 Antagonists Smokers who are poor nicotine metabolizers smoke less Stress triggers relapse in animal models of addiction and CRF antagonists interfere with the response to stress Inhibitors of metabolizing enzymes CRF Antagonists
    • 54. But, drug addiction is a chronic illness with relapse rates similar to those of hypertension, diabetes, and asthma. McLellan et al., JAMA, 2000.
    • 55. McLellan et al., JAMA, 2000. Drug Addiction Type I Diabetes Hypertension 50 to 70% 50 to 70% 90 80 70 60 50 40 30 20 10 0 30 to 50% 100 40 to 60% Percent of Patients Who Relapse Relapse Rates Are Similar for Drug Addiction & Other Chronic Illnesses Asthma
    • 56. Addiction is Similar to Other Chronic Illnesses Because: • It has biological and behavioral components, both of which must be addressed during treatment. • Recovery from it--protracted abstinence and restored functioning--is often a long-term process requiring repeated episodes of treatment. • Relapses can occur during or after treatment, and signal a need for treatment adjustment or reinstatement. • Participation in support programs during and following treatment can be helpful in sustaining long-term recovery Therefore…
    • 57. Full recovery is a challenge but it is possible …
    • 58. Extended Abstinence is Predictive of Sustained Recovery After 5 years – if you are sober, you probably will stay that way. It takes a year of abstinence before less than half relapse Dennis et al, Eval Rev, 2007
    • 59. [C-11]d-threo-methylphenidate DAT Recovery with prolonged abstinence from methamphetamine Normal Control high Methamphetamine Abuser (1 month abstinent) Methamphetamine Abuser (14 months abstinent) Volkow et al., J. Neuroscience, 2001. low
    • 60. Treatment Reduces Drug Use and Recidivism Delaware Work Release Therapeutic Community (CREST) + Aftercare 3 Years After Release (N=448) tr ea tm C R en ES t T D C ro R ES po ut T s C om C pl R et ES er + T s A C fte om rc p ar let e er s N o N o tr ea tm C R en ES t T D C ro R ES po ut T s C om C pl R et ES er + T s A C fte om rc p ar let e er s Percentage of Participants p < 0.05, compared to no treatment group
    • 61. In Treating Addiction… Abst We Need to Keep Our Eye on the Real Targets! in e n ce lity in nctiona ork Fu mily, Wunity Fa Comm and
    • 62. Priority Areas for NIDA Prevention Research (Children & Adolescents) genetics environment development co-morbidity Treatment Research (New Targets & New Strategies) HIV/AIDS Research
    • 63. Drug Use Has Played a Prominent Role in the HIV/AIDS Epidemic In Several Ways • Disease Transmission - IV Drug Use—Needle sharing - Drug Intoxication: Impaired judgment, disinhibition, leading to risky sexual behaviors • Disease Progression • Neurological Complications
    • 64. Drugs of Abuse Have Had A Major Impact on the HIV/AIDS Epidemic 70 Proportions of AIDS Cases in Adults & Adolescents by Exposure in the USA 60 % of Cases 50 Men who have sex with men (MSM) 40 Injection drug use 30 20 Heterosexual contact MSM who inject drugs 10 0 1985 1987 1989 1991 1993 1995 1997 Year of Diagnosis Centers for Disease Control and Prevention (CDC) 1999 2001 2003
    • 65. Convergence of HIV Seroprevalence Among Injecting and Non-injecting Drug Users Drug Treatment Program Respondent-Driven Sampling HIV Prevalence (n=2121 2001-2004) 20 20 15 (n=448 2004) 13% CI 12-15% 12% 15 15% CI 11-19% 17% CI 12-21% CI 9-16% 10 10 5 5 0 0 Current Injectors Non-Injectors Source: Des Jarlais et al AIDS, 21: 231-235, 2007. Current Injectors Non-Injectors
    • 66. The AIDS Epidemic Disproportionately Affects Minority Populations 70 White, not Hispanic 60 % of Cases 50 40 Black, not Hispanic Hispanic 30 20 American Indian/ Alaska Native Asian/Pacific Islander 10 0 1985 1987 1989 1991 1993 1995 1997 Year of Diagnosis Centers for Disease Control and Prevention (CDC) 1999 2001 2003 2005
    • 67. Acceleration of HIV Degeneration of Dopamine Cells With Cocaine
    • 68. NIDA International Program Components Post-Doctoral Research Fellowship Technical Consultation International Research Collaboration Scientific Exchange Information Dissemination
    • 69. Why focus on drug abuse internationally? 15.9 I. Drug abuse is a global phenomenon 13.7 7.9 Millions of Users Cannabis Amphetamines Ecstasy Cocaine Opiates 5 % of people aged 15-64 26.2 II. Intertwined dual-epidemics of drug addiction & HIV/AIDS HIV Infections Attributed to Injection Drug Use and Risky Sexual Behaviors Related to Drug Abuse 160.9 UNODC 2005 World Drug Report III. Take advantage of unique opportunities to advance scientific knowledge through research
    • 70. NIDA Supports International Drug Abuse Research In Numerous Ways Fund international research Provide training and exchange opportunities Set international research priorities Organize & sponsor conferences and meetings Binational agreements Dissemination of information
    • 71. Where Do We Need to Go From Here? We Need to… Advance the SCIENCE and… Erase the STIGMA
    • 72. For More Information NIDA Public Information: www.nida.nih.gov www.drugabuse.gov NIDA International Program: www.international.drugabuse.gov Imelda Medina, M.D. imedina2@med.miami.edu www.drugabuse.gov NIDA NATIONAL INSTITUTE ON DRUG ABUSE

    ×